Registration of Additional Securities (up to 20%) (s-1mef)
January 15 2021 - 6:24AM
Edgar (US Regulatory)
As publicly filed with the Securities
and Exchange Commission on January 15, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933
Lantern Pharma Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
2834
|
|
46-3973463
|
(State or jurisdiction of
|
|
(Primary Standard Industrial
|
|
(I.R.S. Employer
|
incorporation or organization)
|
|
Classification Code Number)
|
|
Identification No.)
|
Lantern Pharma Inc.
|
1920 McKinney Avenue, 7th Floor
|
Dallas, Texas 75201
|
(972) 277-1136
|
(Address, including zip code, and telephone number,
|
including area code, of registrant’s principal executive offices)
|
Panna Sharma
|
President and Chief Executive Officer
|
1920 McKinney Avenue, 7th Floor
|
Dallas, Texas 75201
|
(628) 777-3339
|
(Name, address, including zip code, and telephone number,
|
Including area code, of agent for service)
|
Copies to:
Daniel K. Donahue, Esq.
|
Brad L. Shiffman, Esq.
|
Greenberg Traurig, LLP
|
Blank Rome LLP
|
18565 Jamboree Road, Suite 500
|
1271 Avenue of the Americas
|
Irvine, California 92612
|
New York, New York 10020
|
Telephone: (949) 732-6557
|
Telephone: (212) 885-5442
|
Approximate date
of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.
If any of the securities
being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act
of 1933, check the following box. ☐
If this Form is filed
to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
x File No. 333-251992
If this Form is a post-effective
amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller
reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
|
☐
|
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☒
|
|
Smaller reporting company
|
☒
|
|
|
|
Emerging growth company
|
☒
|
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act ☐
CALCULATION OF REGISTRATION FEE
Title of Each Class of Securities to be Registered
|
|
Proposed
Maximum
Aggregate
Offering
Price(1)(2)
|
|
|
Amount of
Registration
Fee
|
|
Common Stock, par value $0.0001 per share(3)
|
|
$
|
11,499,994
|
|
|
$
|
1,254.65
|
|
|
(1)
|
Represents
only the additional number of shares of common stock being registered, and includes shares of common stock that the underwriters
have the option to purchase. Does not include the securities that the registrant previously registered on the Registration Statement
on Form S-1 (File No. 333-251992).
|
|
(2)
|
Estimated solely for the
purpose of calculating the registration fee in accordance with Rule 457(o) of the Securities Act of 1933.
|
This Registration Statement shall become effective upon filing
with the Securities and Exchange Commission in accordance with Rule 462(b) of the Securities Act.
EXPLANATORY NOTE
This Registration Statement
is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Securities Act”) and General
Instruction V of Form S-1. The contents of the Registration Statement on Form S-1 (File No. 333-251992), including the exhibits
thereto, filed by Lantern Pharma Inc. with the Securities and Exchange Commission (the “Commission”) pursuant to the
Securities Act, which was declared effective by the Commission on January 14, 2021, are incorporated by reference into this Registration
Statement.
PART II - INFORMATION NOT REQUIRED IN
PROSPECTUS
Item 16. Exhibits and Financial Statement
Schedules
(a) Exhibits
The following exhibits
are filed herewith or incorporated by reference in this prospectus:
|
*
|
Previously filed with the Registrant's Registration Statement on Form S-1 (File No. 333-251992), initially filed with the Securities and Exchange Commission January 8, 2021 and incorporated by reference herein
|
SIGNATURES
Pursuant to the requirements
of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Dallas, State of Texas, on January 15, 2021.
|
Lantern Pharma Inc.
|
|
|
|
By:
|
/s/ Panna Sharma
|
|
|
Panna Sharma
|
|
|
Chief Executive Officer
(Principal Executive Officer)
|
Pursuant to the requirements
of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the
dates indicated.
Name
|
|
Title
|
|
Date
|
/s/ Panna Sharma
|
|
President, Chief Executive Officer and
Director
|
|
January 15, 2021
|
Panna Sharma
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ David R. Margrave
|
|
Chief Financial Officer
|
|
January 15, 2021
|
David R. Margrave
|
|
(Principal Financial and Principal Accounting Officer)
|
|
|
|
|
|
|
|
*
|
|
|
|
|
Donald J. Keyser
|
|
Chairman of the Board
|
|
January 15, 2021
|
|
|
|
|
|
*
|
|
|
|
|
Leslie W. Kreis, Jr.
|
|
Director
|
|
January 15, 2021
|
|
|
|
|
|
*
|
|
|
|
|
David S. Silberstein
|
|
Director
|
|
January 15, 2021
|
|
|
|
|
|
*
|
|
|
|
|
Vijay Chandru
|
|
Director
|
|
January 15, 2021
|
|
|
|
|
|
*
|
|
|
|
|
Franklyn Prendergast
|
|
Director
|
|
January 15, 2021
|
By:
|
/s/ Panna Sharma
|
|
|
Panna Sharma
|
|
|
Attorney-in-Fact
|
|
II-2
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024